Elron Ventures Ltd · TASE:ELRN
Elron Ventures — Elron Electronic Industries — Investor Presentation (March 2011)
33 slides from Elron Ventures's investor presentation, March 2011
Slide 1: Company Presentation March 2011
COMPANY PRESENTATION MARCH 2011
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers. Elron may make improvements and/or changes in the fe
Slide 3: 3
3
Slide 4: Elron 09-10
ELRON 09-10 In the first half of 2009, Elron began implementing a series of management and organizational measures FOCUSING ACTIVITIES IDENTIFYING OPPORTUNITIES REDUCING COSTS
Slide 5: Focusing investments in core companies
ELRON 09-10 FOCUSING INVESTMENTS IN CORE COMPANIES Reducing investments in companies with limited potential
Slide 6: Reduction in number of group companies
ee | a t ELRON 09-10 K 4 aS fat From 2008 to 2010 the number of group companies was reduced by
Slide 7: Investments and Exits 2006-2010
ELRON 09-10 Investments and Exits 2006-2010 160 - 89.6 million $ 68.5 million $ 53.8 million $ 2.7 2.1 million $ million $ 0 [eromac] = =e 2006 2007 2009 2010 | nvestments m Exits Mi * including earn-out and escrow amounts from the sale ofMedingo ef. a eS
Slide 8: 8
8
Slide 9: Investments Realization: Sale of Medingo
INVESTMENTS REALIZATION May 2010 Sale of Medingo to F. Hoffman-LaiRoche in Switzerland for ~$'200,000,000 CcOog@s { K\ D 4 Vee N bi Lael ' *The proceeds from the sale of Medingo include earn-out and escrow amounts.
Slide 10: October 2009: Sale of NetVision
October 2009 Sale of Elron's noangs in NetVisiontoIDB ~ group companies for | . ee 000,000 hig
Slide 11: Investments Realization: Sale of Teledata
INVESTMENTS REALIZATION SOW Me June 2010 Sale of Teledata by way of merger to yy Enablence in Canada for ~$50,000, 000 @ > ert NETWORKS L “4 a
Slide 12: Management changes and G&A cost decrease
ELRON 09-10 New management team appointed Manpower reduced by half Entered into Services Agreement with DIC DECREASE IN CORPORATE G&A COSTS (compared to 2008) 5.6 million $ 12
Slide 13: Income (Loss) Development 2008-2010
ELRON 09-10 Income (Loss)* Development 2008-2010 Medingo and Teledata Exits million $ NetVision Exit 3DV Exit La nes million $ 4.5 2s million $ 12.2 11.5 12.9 14 7 million $ million $ i a U3 17.7 ment saies million $ 24.0 million $ Qijos = Q2z/os 3/08 = Qa/osS 1/0 Qz/o9 = 3/09 Quo Qui Qasit Q3/10 —Q
Slide 14: Net income for 2010 amounted to ~$61 million
ELRON 09-10 Net income * for 2010 amounted to ~$61 million * attributable to Company's shareholders 14
Slide 15: Spotlight 2011
; le Te . ; pee [ er sSPOTLIGHT 20" Le
Slide 16: Spotlight 2011
SPOTLIGHT 2011 16
Slide 17: Pocared: high throughput IVD system
SPOTLIGHT 2011 High throughput in-vitro diagnostics (IVD) system. Rapid, automated microbiological testing of pathogens in body fluids based on optical technology. Real-time diagnosis, whereas current methods take 24-72 hrs. Automated, whereas current methods require highly-trained technician teams.
Slide 18: Pocared next milestones
SPOTLIGHT 2011 Pocared expects to commence a broad diagnostic clinical trial during the second half of 2011. Also, Pocared intends to act toward obtaining the CE Mark for the product under its development during 2011. 18
Slide 19: BrainsGate: platform for CNS diseases
SPOTLIGHT 2011 Broad platform technology for treatment of central nervous system diseases. Stimulates the SPG (a nerve center located behind the nasal cavity) to increase blood flow to the brain using a miniature implantable electrode. Additional investors include Johnson & Johnson. Enables treatmen
Slide 20: BrainsGate next milestone
SPOTLIGHT 2011 D BrainsGate Delivering new hope to the mind NEXT MILESTONE BrainsGate is working towards improving its clinical trial protocol, and expects to commence an IDE clinical trial based on a new protocol during 2011. 20
Slide 21: NuLens: accommodating intraocular lens
SPOTLIGHT 2011 First real accommodating intraocular lens ("IOL") for implantation in Cataract and Impaired Vision patients. Additional investors include Warburg Pincus. Expected to provide over 6 diopters of accommodative power compared to 1-2 diopters today. Designed to mimic the natural function o
Slide 22: NuLens next milestone
SPOTLIGHT 2011 ONuLens::: NEXT MILESTONE NuLens expects to commence an IDE Clinical trial during the first half of 2012. 22
Slide 23: Development stages to revenues
Initial R&D / IDE / FDA CE-/FDA-clearance Initial Revenues Accelerated Significant ClinicalTrials Trials / Pre-commercialization Revenues Revenues
Slide 24: Looking Forward
LOOKING FORWARD
Slide 25: Elron's assets
LOOKING FORWARD > ELRON'S ASSETS Networked team Access to IDB group Deal Flow Proven success in building break- through companies One of Israel's most influential business enterprises Leading corpora- tions in insurance & capital markets, com- munications, tech- nology, industry, real estate develop
Slide 26: Looking Forward: strategy
be . LOOKING FORWARD - * a anced The Company is continuing to implement a strategy of identify- ing and building leading companies based on Israeli technology. Seeking investments with a focus on medical devices, in which Elron has experience, connections & proven capabilities. Continuing to invest
Slide 27: Implementing Elron's Strategy
LOOKING FORWARD Implementing Elron's Strategy 2005 2007S 2007 2010-—“— November 2005 November 2007 July 2009 | May2010 si * cumulative investment
Slide 28: Identifying Opportunities: Investment in Kyma
LOOKING FORWARD Identifying Opportunities: Investment in Miniature, radar technology based device for the continuous monitoring of chronic heart failure (CHF) patients. The device comprises of a miniature patch attached to the patient's torso. Technological Advantage Data is transferred wirelessly,
Slide 29: 29
29
Slide 30: Finance: 2010 Results
FINANCE 2010 Results 2008 2009 2010 Net Income for 2010 pose i attributable to (71.8) (143) 60.7 (5 million) shareholders Main contributors to Equity in losses of group companies 56.1 27.4 23.7 income (loss) ($ millions)* * net of non-controlling interest and of tax — Excess cost amortization 5.0 5.
Slide 31: Statement of Financial Position
Cash and cash equivalents 56.5 STAT E M FE N T Current assets and assets held for sale (excluding cash) 30.3 Long-term investments 129.6 O F Property, plant & equipment, net 21 Intangible assets 3.6 F } N A N C { A L Other long-term receivables 28.3 nL oi nn FINANCE a, 64,7 9.2 127.8 PO S | Tl O N C
Slide 32: Net cash development
Net cash development “30 40.7 m 30.0 23.8 million $ 30, millionS 13.2 ") million $ 3.2 10 million $ 20 12.5 “5 i million $ 50 — AS , ae a millions §=39.0 - million $ Q2/o8 Q3/08 Q4/o8 Qi/o9 Q2/09 Q3/09 Qa/o9 Qi/10 Q2/10 Q3/10 Q4/10
Slide 33: Elron Electronic Industries Ltd
ELRON ELECTRONIC INDUSTRIES LTD WWW.ELRON.COM +972-3-6075555 ELRON@ELRON.COM
Elron Electronic Industries — Investor Presentation (March 2011) on 6ix